These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

781 related articles for article (PubMed ID: 24586709)

  • 1. PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer.
    Guo Z; Wang X; Cheng D; Xia Z; Luan M; Zhang S
    PLoS One; 2014; 9(2):e89350. PubMed ID: 24586709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
    Lu L; Xu X; Zhang B; Zhang R; Ji H; Wang X
    J Transl Med; 2014 Feb; 12():36. PubMed ID: 24502656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer.
    Guo Z; Cheng D; Xia Z; Luan M; Wu L; Wang G; Zhang S
    J Transl Med; 2013 Sep; 11():215. PubMed ID: 24044888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
    Guo Z; Wang H; Meng F; Li J; Zhang S
    J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carboplatin and programmed death-ligand 1 blockade synergistically produce a similar antitumor effect to carboplatin alone in murine ID8 ovarian cancer model.
    Zhu X; Xu J; Cai H; Lang J
    J Obstet Gynaecol Res; 2018 Feb; 44(2):303-311. PubMed ID: 29171115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.
    Messenheimer DJ; Jensen SM; Afentoulis ME; Wegmann KW; Feng Z; Friedman DJ; Gough MJ; Urba WJ; Fox BA
    Clin Cancer Res; 2017 Oct; 23(20):6165-6177. PubMed ID: 28855348
    [No Abstract]   [Full Text] [Related]  

  • 7. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer.
    Duraiswamy J; Freeman GJ; Coukos G
    Cancer Res; 2013 Dec; 73(23):6900-12. PubMed ID: 23975756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.
    Weir GM; Hrytsenko O; Quinton T; Berinstein NL; Stanford MM; Mansour M
    J Immunother Cancer; 2016; 4():68. PubMed ID: 27777777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
    Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
    Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells.
    John LB; Devaud C; Duong CP; Yong CS; Beavis PA; Haynes NM; Chow MT; Smyth MJ; Kershaw MH; Darcy PK
    Clin Cancer Res; 2013 Oct; 19(20):5636-46. PubMed ID: 23873688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In Situ.
    Moran AE; Polesso F; Weinberg AD
    J Immunol; 2016 Sep; 197(6):2509-21. PubMed ID: 27503208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PLGA-nanoparticle mediated delivery of anti-OX40 monoclonal antibody enhances anti-tumor cytotoxic T cell responses.
    Chen M; Ouyang H; Zhou S; Li J; Ye Y
    Cell Immunol; 2014 Feb; 287(2):91-9. PubMed ID: 24487032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti-PD1-Resistant Lung Tumor Model.
    Niknam S; Barsoumian HB; Schoenhals JE; Jackson HL; Yanamandra N; Caetano MS; Li A; Younes AI; Cadena A; Cushman TR; Chang JY; Nguyen QN; Gomez DR; Diab A; Heymach JV; Hwu P; Cortez MA; Welsh JW
    Clin Cancer Res; 2018 Nov; 24(22):5735-5743. PubMed ID: 29784675
    [No Abstract]   [Full Text] [Related]  

  • 14. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.
    Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C
    Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo antitumor function of tumor antigen-specific CTLs generated in the presence of OX40 co-stimulation in vitro.
    Pham Minh N; Murata S; Kitamura N; Ueki T; Kojima M; Miyake T; Takebayashi K; Kodama H; Mekata E; Tani M
    Int J Cancer; 2018 Jun; 142(11):2335-2343. PubMed ID: 29313971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Robust Antitumor Effects of Combined Anti-CD4-Depleting Antibody and Anti-PD-1/PD-L1 Immune Checkpoint Antibody Treatment in Mice.
    Ueha S; Yokochi S; Ishiwata Y; Ogiwara H; Chand K; Nakajima T; Hachiga K; Shichino S; Terashima Y; Toda E; Shand FH; Kakimi K; Ito S; Matsushima K
    Cancer Immunol Res; 2015 Jun; 3(6):631-40. PubMed ID: 25711759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
    Allard B; Pommey S; Smyth MJ; Stagg J
    Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity.
    Redmond WL; Linch SN; Kasiewicz MJ
    Cancer Immunol Res; 2014 Feb; 2(2):142-53. PubMed ID: 24778278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer.
    Zhu X; Lang J
    J Gynecol Oncol; 2017 Sep; 28(5):e64. PubMed ID: 28657225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis.
    Garrison K; Hahn T; Lee WC; Ling LE; Weinberg AD; Akporiaye ET
    Cancer Immunol Immunother; 2012 Apr; 61(4):511-21. PubMed ID: 21971588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.